Related coverage linked through entity extraction aliases.
Jul 01, 2026
Johnson & Johnson plans a $1B Pennsylvania cell therapy facility and ranked ninth in Gartner's 2026 supply chain ranking. It also committed $1B to a Jacksonville contact lens plant.
May 25, 2026
New market reports project strong growth in pharmaceutical manufacturing: fill-finish is set to reach $21.04 billion by 2030, ampoule filling/sealing machines to grow at a 5.8% CAGR through 2035, and medical membranes to hit $6.6 billion by 2030.
Aug 09, 2026
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Jul 07, 2026
BostonGene won the "Overall AI-based Analytics Company of the Year" award in the 9th annual AI Breakthrough Awards. Its platform pairs AI with molecular profiling to support oncology drug development decisions.
Aug 04, 2026
Revolution Medicines (RVMD) shares up 132% YTD. Daraxonrasib beat chemo in pancreatic cancer (13.2 vs 6.7 months median OS). Company has no marketed products and a $39B valuation.
May 28, 2026
The Trump administration barred NIAID officials from WHO meetings, reclaimed $600M from four states, and faced a Senate report showing drug prices rising despite deals. New drugs average $353K a year.
Jul 10, 2026
AI is transforming cardiovascular medicine: $1.4B+ in investments, a new cardiac biomarker sensor, and stroke-imaging software in 2,500+ hospitals. FDA, EMA, and PMDA are opening clearer regulatory pathways.
Feb 24, 2026
Myriad Genetics, uniQure, and Legend Biotech have scheduled Q4 and full year 2025 earnings calls for Feb 23, Mar 2, and Mar 10, 2026, respectively. Details include webcast access, dial-in numbers, and company background.
Jul 22, 2026
A large clinical trial found that adding apalutamide to hormone therapy before and after prostate cancer surgery improves outcomes for high-risk patients. NHS England will roll out SABR radiotherapy requiring only five sessions, and new ctDNA and robotic biopsy technologies are advancing prostate cancer care.
Aug 05, 2026
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
Jul 27, 2026
IBBQ posted a 43.6% one-year return and 38% max drawdown, while IBB has $9.61B AUM and no dividends. IBBQ outperformed VHT and IXJ over one year but with higher volatility.
Jul 30, 2026
Novartis AG is selling its 70.68% controlling stake in Novartis India to ChrysCapital for $175 million, triggering a mandatory open offer at INR 860.64 per share. Shares surged 20% as the Swiss drugmaker shifts investment to US manufacturing amid tariff risks.
Jul 27, 2026
Trump’s phased tariffs on medicines spur over $400 billion in US pharma investments. Indian generic makers face a 2028 deadline to adapt.
Jul 25, 2026
Flow chemistry, laboratory mixer, and industrial extruder markets are projected to grow significantly through 2035, driven by pharmaceutical continuous manufacturing, high R&D funding, and sustainability trends. Flow chemistry is expected to reach $12 billion, while laboratory mixers could hit $29.6 billion. Key players include Merck KGaA, BASF, and Lonza.
Jul 20, 2026
A study in JAMA Open finds that anti-kickback penalties paid by pharma companies amounted to just 2.2% of U.S. revenue from involved drugs. Pfizer recently disclosed $60,000 in lobbying on drug pricing and vaccine issues. Researchers say settlements act as a cost of doing business.
Jul 16, 2026
Johnson & Johnson is preparing a potential sale of its DePuy Synthes orthopedics unit, valued at over $20 billion, with private equity firms showing interest. Concurrently, the unit has acquired spine implant maker Expanding Innovations to bolster its technology portfolio.
Jul 15, 2026
Long-term QUASAR extension data show Tremfya (guselkumab) maintained clinical and endoscopic remission in ulcerative colitis through Week 140, with 80.8% in clinical remission and no new safety signals.
Jun 25, 2026
The US FTC is challenging a court ruling involving Johnson & Johnson's patent acquisition for Stelara, arguing it could weaken antitrust enforcement in pharma. Separately, Turkey's Court of Cassation ruled that patent holders who file infringement actions and send warning letters to third parties are exercising lawful patent rights, dismissing an unfair competition claim by a generic company.
Jun 23, 2026
The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.
Jun 09, 2026
The FDA is receiving extensive industry feedback on three regulatory initiatives: draft guidance for using new approach methodologies to reduce animal testing, the Commissioner's National Priority Voucher pilot program, and a proposed rule to update the National Drug Code format. Stakeholders are urging revisions to the NAMs guidance, improvements to the CNPV program, and timely finalization of the NDC rule to avoid disruptions.
